About Waters Corporation (NYSE:WAT)
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. It also designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA product line. It is also a developer and supplier of software-based products that interface with the Company's instruments, as well as other suppliers' instruments. Its LC and LC-MS instruments are utilized in a range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify a range of compounds.
Industry, Sector and Symbol
Industry Advanced Medical Equipment & Technology
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Trailing P/E Ratio27.51
Forward P/E Ratio26.49
Sales & Book Value
Annual Sales$2.17 billion
Price / Sales7.21
Cash Flow$7.83 per share
Price / Cash25.11
Book Value$33.06 per share
Price / Book5.95
Net Income$521.50 million
Return on Equity23.61%
Return on Assets11.84%
Frequently Asked Questions for Waters Corporation (NYSE:WAT)
What is Waters Corporation's stock symbol?
Waters Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."
How will Waters Corporation's stock buyback program work?
Waters Corporation announced that its board has approved a share repurchase program on Sunday, June 4th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 7.3% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its shares are undervalued.
How were Waters Corporation's earnings last quarter?
Waters Corporation (NYSE:WAT) posted its earnings results on Tuesday, October, 24th. The medical instruments supplier reported $1.77 EPS for the quarter, topping the consensus estimate of $1.74 by $0.03. The medical instruments supplier had revenue of $565.58 million for the quarter, compared to analysts' expectations of $555.25 million. Waters Corporation had a return on equity of 23.61% and a net margin of 24.34%. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.57 EPS. View Waters Corporation's Earnings History.
When will Waters Corporation make its next earnings announcement?
Where is Waters Corporation's stock going? Where will Waters Corporation's stock price be in 2017?
15 brokers have issued 1 year target prices for Waters Corporation's stock. Their predictions range from $175.00 to $205.00. On average, they anticipate Waters Corporation's share price to reach $192.17 in the next year. View Analyst Ratings for Waters Corporation.
What are Wall Street analysts saying about Waters Corporation stock?
Here are some recent quotes from research analysts about Waters Corporation stock:
- 1. According to Zacks Investment Research, "Waters Corp.’s third-quarter 2017 earnings grew an impressive 12.7% year over year and topped the Zacks Consensus Estimate by 1.7%. Going forward, the company believes that stable demand from pharmaceutical business, steady recurring revenues, strength in Asia and modest recovery in industrial markets will accelerate its momentum. Based on these dynamics, the company is expecting strong mid-single-digit constant currency sales increase in 2017. Even the government and academic markets have returned to the growth track after sustained weakness. However, the company’s growth will likely be hindered by contracting demand in the Americas. Waters Corp. also intends to increase its spending on research and development in the coming quarters, which, although beneficial in the long run, will push expenses higher and hurt immediate profits. Further, shares of Waters Corp. have underperformed the industry’s average return over past year." (10/26/2017)
- 2. Deutsche Bank AG analysts commented, "needle-movers" that could generate growth for the next year.Finally, the increase in Leonard's price target merely reflects an expansion in the peer multiple and a six-month roll-forward of his valuation period.Related Links:Benzinga's Top Upgrades, Downgrades For July 10, 2017Pressure Biosciences CEO On Its Beaten Down Stock: 'We Can Now Begin To Focus On The Area That Is Most Important'______Image Credit: By NASA [Public domain], via Wikimedia Commons Posted-In: Dan Leonard Deutsche Bank ToolsAnalyst Color Downgrades Price Target Analyst Ratings Tech Best of Benzinga © 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Related Articles (WAT) Benzinga's Top Upgrades, Downgrades For July 10, 2017 View Comments and Join the Discussion! View the discussion thread. document.write('') Newsletter & Alerts